A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a
novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor
cell division leading to tumor growth), can reduce tumor sizes in patients with bladder
cancer